An Early Phase 1 interventional study of red yeast rice,RYR in Polycystic Ovary Syndrome (PCOS), sponsored by Sichuan Provincial People's Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-08-06.
Sponsored by Sichuan Provincial People's Hospital · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Polycystic Ovary Syndrome with a site in China — 29 open to participants now, 33 under way, none of them phase 3. Polycystic Ovary Syndrome · China.
Among the 107 studies in Polycystic Ovary Syndrome with a site in China, this one is the 49th largest by planned enrollment of the 86 interventional ones that give a count, is one of 10 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 15 of the 32 other live ones, and was the 94th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →29 of the 107 studies in Polycystic Ovary Syndrome with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–40 · Women only · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40 · Women only
Shanghai First Maternity and Infant Hospital · Sites in China
Ages 19–40 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 7 · Phase 4 14
First in 2008; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 100 across the 86 interventional studies, 300 across the 21 observational. Of the 37 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 107 have an industry lead sponsor. The 10 most frequent:
Sichuan Provincial People's Hospital is the lead sponsor of 78 studies on the registry; 43 are open to participants now.
Sichuan Provincial People's Hospital has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Polycystic Ovary Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07739940Guangdong Women and Children HospitalClinical Research Cohort for Polycystic Ovary Syndrome | 2026-12-01 |
| NCT07739953Guangdong Women and Children HospitalDevelopment and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome | 2026-12-31 |
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
| NCT07616037Shanghai Zhongshan HospitalEfficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 107 studies in Polycystic Ovary Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to elucidate the effects of red yeast rice on the improvement of symptoms in patients with polycystic ovary syndrome(PCOS), and to analyze the dose-response relationship between intestinal microbiota and its metabolite, hydroxyindole, and clinical indicators of PCOS.
The main questions it aims to answer are:
How effective is red yeast rice in treating PCOS? Does the indole metabolic pathway of gut microbiota play a crucial role in the improvement of PCOS symptoms by red yeast rice? Participants will take 6 grams of red yeast rice daily for 6 months, and records will be kept of their PCOS clinical symptoms and indicators before the intervention, at the 3rd month post-intervention, and at the 6th month post-intervention. Additionally, biological samples from feces and serum will be collected at these time points.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Red yeast rice (RYR), a fermented product that has both medicinal and edible properties, is one of the traditional Chinese medicines used in the treatment of metabolic diseases. The main components of red yeast rice include monacolins, monacolin K, red yeast rice pigments, ergosterol, stigmasterol, β-sitosterol, daucosterol.
Drug: red yeast rice,RYR
Participants will take 6 grams of red yeast rice daily for 6 months.
inflammatory marker IL18 [pg/ml]
Time frame: Baseline, the 3rd month and the 6th month after the intervention
inflammatory marker IL1β [pg/ml]
Time frame: Baseline, the 3rd month and the 6th month after the intervention
testosterone (nmol/l)
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Follicle - Stimulating Hormone (mIU/mL)
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Luteinizing Hormone (mIU/mL)
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Estradiol (pmol/l)
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Progesterone (ng/mL)
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Prolactin (ng/mL)
Time frame: Baseline, the 3rd month and the 6th month after the intervention
follicles number
The number of follicles in each ovary of each participant will be determined by ultrasonography.
Time frame: Baseline, the 3rd month and the 6th month after the intervention
ovarian volume(Length x Width x Thickness/2,ml)
The size of each ovary in each participant will be determined by ultrasonography.
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Follicle diameter(mm)
The diameter of the follicles will be determined by ultrasonography.
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Hydroxyindole concentration
Time frame: Baseline, the 3rd month and the 6th month after the intervention
Body-mass-index (BMI)
BMI measured with the formula BMI=weight \[kg\]/height² \[m\]
Time frame: Baseline, the 3rd month and the 6th month after the intervention
waist-to-hip ratio
Calculated with the formula: waist circumference/hip circumference
Time frame: Baseline, the 3rd month and the 6th month after the intervention
The metagenomics of fecal samples
Total DNA of fecal samples is extracted by CTAB method.
Time frame: before the intervention, at the 3rd month and the 6th month after the intervention
Non-targeted metabolomic analysis of fecal and serum samples
Fecal and serum samples were subjected to untargeted metabolomic detection using LC-MS/MS with an Agilent UHPLC system coupled to an Agilent 6538 UHD and Accurate-Mass Q-TOF mass spectrometer. Metabolites in the samples were separated, identified, and their information was acquired. Univariate and multivariate analyses were performed on the metabolites to screen for significantly differential metabolites before and after treatment.
Time frame: before the intervention, at the 3rd month and the 6th month after the intervention
Started Jul 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.
Of 27 phase 1 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 147. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan Provincial People's Hospital